On 23 April 2026, the Council of the EU adopted its 20th package of restrictive measures against Russia – a landmark decision that, for the first time, introduces dedicated sanctions mechanisms targeting the realm of intellectual property.
From 1 September 2026, new rules for calculating remuneration for employees who are the authors of employee inventions, utility models and industrial designs will come into force. The document fundamentally changes the approach to such payments.
The Russian Ministry of Health’s draft law “On Amending Certain Legislative Acts of the Russian Federation…” (“the Draft Law”), concerning changes to the control of the circulation of medicinal products has been published on the federal portal for draft regulatory acts.
The Lidings team, led by Managing Partner Boris Malakhov and including Senior Associate Vladislav Ryabov, Associate Ivan Vasiliev, and Junior Associate Alena Troitskaya, advised the client in the dispute concerning intellectual property and brand protection in the Russian Federation.
Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2026 the firm is ranked among the TOP leading legal advisors in Russia.
April 9th,2026 annual conference Pharmaceuticals – 2026: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.
As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2025 and what awaits us in 2026.
India has long and firmly established itself as the ‘pharmacy of the world’, as the country produces a fifth of all generics and provides affordable medicines to millions of people across the globe. However, India is now transitioning from copying innovative molecules to creating them. Amid the restructuring of global supply chains and strategic rapprochement with Russia, India is becoming both a battleground for fierce patent wars and a unique laboratory for joint research. How can Russian pharmaceutical companies establish intellectual property protection in a jurisdiction where the balance between the interests of pharmaceutical giants and the affordability of medicines for the population is enshrined in law? Boris Malakhov and Natalya Thotahewage analyse the key features of patenting and the prospects for technological alliances between Moscow and Delhi.
The site uses cookie technology to ensure optimal performance, analyze usage and improve user experience. By continuing to use the site, you consent to the placement of cookies on your device on the terms set out in the Privacy Policy.
To ensure optimal performance, analyze usage and improve user experience, the website may use web analytics systems (including Yandex.Metrica), which may place cookies on your device.
By continuing to use the website, you agree to the use of these technologies and the placement of cookies. You can delete cookies from your device through your browser settings and you can block the placement of cookies, however, in doing so, some website features may not be available due to the engine's technological limitations.
You can find more information in the Privacy Policy.